Healthcare company Otsuka Pharmaceutical Co Ltd reported on Wednesday the launch of a license agreement to commercialise delamanid for the treatment of adults with pulmonary multidrug-resistant tuberculosis (MDR-TB) in low- and middle-income countries in partnership with Mylan NV (Nasdaq:MYL)(TASE:MYL).
The license agreement for Delamanid, which was discovered and developed and is currently marketed by Otsuka under the brand name Deltyba, has been signed between the company's respective subsidiaries, Otsuka Novel Products GmbH (ONPG) and Mylan Pharmaceuticals Private Limited.
This agreement provides Mylan with an exclusive license by Otsuka to prioritize access to Deltyba in South Africa and India. The Drug Controller General of India (DCGI) has granted approval to Mylan to market Deltyba in India and registration is under way in South Africa.
Additionally, Mylan will further exercise exclusive commercial rights and registration responsibilities in additional high MDR-TB burden countries. Both companies may enter into discussions and feasibility studies for a technology transfer plan, enabling Mylan to manufacture and distribute Deltyba for these markets in the future.
Deltyba is one of two anti-tuberculosis medicines and is registered in the EU, Japan, Korea, Hong Kong, Turkey and India. The efficacy of Deltyba was studied in a large, randomised, placebo-controlled phase 2 trial that demonstrated the drug is well tolerated with adverse events evenly distributed in the Deltyba and placebo treatment groups. Electrocardiogram QT prolongation was reported in 9.9% of patients receiving in 100 mg twice daily compared to 3.8% of patients receiving placebo plus OBR.
Tuberculosis (TB), an airborne infectious disease, is among the top causes of death in the world and is the leading infectious disease killer. In 2015, nearly half a million people globally developed MDR-TB, an infection resistant to at least isoniazid and rifampicin, the two most commonly used first-line TB drugs.
Quanterix partners with leading health networks for Alzheimer's diagnosis advancements
Precision BioSciences reports FDA pre-IND feedback for PBGENE-HBV
VBI to sell manufacturing capabilities and enter new license agreement with Brii Biosciences
Ondine Biomedical's Steriwave shows promise in nasal pathogen reduction
BioSenic expands patent coverage for ATO therapeutic platform
PacBio unveils Nanobind PanDNA kit for enhanced DNA extraction solutions
Sequentify receives funding from Israel Innovation Authority
INOVIO plans BLA submission for INO-3107 as RRP treatment
ImmunityBio secures USD320m investment from Oberland Capital
Poolbeg Pharma prioritises promising RSV drug candidates identified through AI-led analysis
GHIT fund invests JPY500m in antimalarial drug clinical trial
AstraZeneca agrees acquisition of Icosavax
Versameb names new chairman of the board
Kling Bio appoints Dr Stefano Gullà as chief scientific officer